NEW YORK (GenomeWeb) – Bruker said this week that it plans to make additional regulatory submissions for its MALDI Biotyper microbiology platform in the middle of this year.

In support of these planned submission, the company has launched a multi-site clinical trial for the instrument for validation of it for identification of rare Gram-negative bacteria, aerobic Gram-positive bacteria, yeasts, and anaerobic microorganisms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.